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ABSTRACT
ObjeCtive
To determine whether the treatment effect of apixaban 
versus warfarin differs with increasing numbers of 
concomitant drugs used by patients with atrial 
fibrillation.
Design
Post hoc analysis performed in 2015 of results from 
ARISTOTLE (apixaban for reduction in stroke and other 
thromboembolic events in atrial fibrillation)—a 
multicentre, double blind, double dummy trial that 
started in 2006 and ended in 2011.
PartiCiPants
18 201 ARISTOTLE trial participants.
interventiOns
In the ARISTOTLE trial, patients were randomised to 
either 5 mg apixaban twice daily (n=9120) or warfarin 
(target international normalised ratio range 2.0-3.0; 
n=9081). In the post hoc analysis, patients were 
divided into groups according to the number of 
concomitant drug treatments used at baseline (0-5, 
6-8, ≥9 drugs) with a median follow-up of 1.8 years. 
Main OutCOMe Measures
Clinical outcomes and treatment effects of apixaban 
versus warfarin (adjusted for age, sex, and country).
results
Each patient used a median of six drugs (interquartile 
range 5-9); polypharmacy (≥5 drugs) was seen in 
13 932 (76.5%) patients. Greater numbers of 
concomitant drugs were used in older patients, 
women, and patients in the United States. The number 
of comorbidities increased across groups of increasing 
numbers of drugs (0-5, 6-8, ≥9 drugs), as did the 
proportions of patients treated with drugs that interact 
with warfarin or apixaban. Mortality also rose 
significantly with the number of drug treatments 
(P<0.001), as did rates of stroke or systemic embolism 
(1.29, 1.48, and 1.57 per 100 patient years, for 0-5, 6-8, 
and ≥9 drugs, respectively) and major bleeding (1.91, 
2.46, and 3.88 per 100 patient years, respectively). 
Relative risk reductions in stroke or systemic embolism 
for apixaban versus warfarin were consistent, 
regardless of the number of concomitant drugs 
(Pinteraction=0.82). A smaller reduction in major bleeding 
was seen with apixaban versus warfarin with 
increasing numbers of concomitant drugs 
(Pinteraction=0.017). Patients with interacting 
(potentiating) drugs for warfarin or apixaban had 
similar outcomes and consistent treatment effects of 
apixaban versus warfarin.
COnClusiOns
In the ARISTOTLE trial, three quarters of patients had 
polypharmacy; this subgroup had an increased 
comorbidity, more interacting drugs, increased 
mortality, and higher rates of thromboembolic and 
bleeding complications. In terms of a potential 
differential response to anticoagulation therapy in 
patients with atrial fibrillation and polypharmacy, 
apixaban was more effective than warfarin, and is at 
least just as safe.
trial registratiOn
ARISTOTLE trial, ClinicalTrials.gov NCT00412984.
Introduction
In an era of increasing life expectancy, and with a grow-
ing population of survivors with various comorbidities, 
clinical decision making with regard to antithrombotic 
therapy for atrial fibrillation has become an even 
greater clinical challenge.1  Despite the well appreciated 
risk of stroke, oral anticoagulation is often not pre-
scribed in older people, and undertreatment has been 
associated with adverse outcomes.2 3  However, physi-
cians increasingly acknowledge that treatment deci-
sions should probably be based on biological age rather 
than chronological age.4
In various populations, polypharmacy has been 
associated with multiple comorbidities and frailty.5-10 
Moreover, the risk of drug-drug interactions increases 
WhAT IS AlReAdy knoWn on ThIS TopIC
Polypharmacy is associated with increased comorbidity, frailty, and drug-drug 
interactions, and has repeatedly been shown to be a marker of adverse clinical 
outcome; therefore, patients with polypharmacy could have a differential response 
to anticoagulation therapy
For patients with atrial fibrillation, apixaban has been more effective and safer than 
warfarin, but whether this also holds true for patients using many concomitant 
drugs is unknown
WhAT ThIS STudy AddS
For patients with atrial fibrillation, apixaban was more effective than warfarin 
regardless of the number of concomitant drugs used
Although major bleeding rates were consistently lower with apixaban than with 
warfarin, the magnitude of benefit with apixaban seemed to decrease with the 
increasing number of concomitant drug treatments
In this patient group, the specific use of warfarin or apixaban potentiating drugs did 
not seem to account for this differential response to anticoagulation therapy with 
regard to major bleeding
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with the number of concomitant drug treatments. In 
addition, polypharmacy has been related to a higher 
risk of death and bleeding complications, also in 
patients with atrial fibrillation.6-17 In this context, 
patients with polypharmacy could have a differential 
response to anticoagulation therapy.
With the introduction of apixaban, a safer alternative 
to warfarin has become available that has also proven 
to be of value in patients considered unsuitable for 
 warfarin treatment.18 19 In a previous report, we 
 demonstrated that the benefits of apixaban versus 
 warfarin were irrespective of age (<65 years v 65-74 years 
v ≥75 years).20  However, among the elderly population, 
there are patients with hardly any comorbidity, whereas 
there are also younger patients with clinically signifi-
cant comorbidity. On average, patients with atrial fibril-
lation use about four to six different drug treatments.10-21 
Given that polypharmacy is generally defined as the use 
of five or more concomitant drug treatments, and thus 
represents an everyday issue, additional information on 
the effect of oral anticoagulation drugs in this subset of 
patients is of clinical importance.22 Especially in the 
case of apixaban, information on the effect of potentiat-
ing drugs is limited, and is of interest in patients treated 
with many concomitant drugs.
In this context, we performed a post hoc analysis of 
the ARISTOTLE trial (apixaban for reduction of stroke 
and other thromboembolic events in atrial fibrillation) 
to assess the association between the number of drugs 
used and the extent of comorbidity and adverse out-
come.19 In addition, we looked at the relative treatment 
effect of apixaban versus warfarin in relation to the 
number of concomitant drug treatments.
Methods
Patients
The study design and main outcomes of the ARISTO-
TLE trial have been reported previously.19 23 In brief, 
ARISTOTLE was a multicentre, double blind, double 
dummy trial comparing apixaban with warfarin per-
formed in 2006-11. Patients with documented atrial 
fibrillation or atrial flutter were eligible for inclusion if 
one or more of the following risk factors for thrombo-
embolism were present: symptomatic heart failure 
within three months before inclusion or left ventricular 
function 40% or less; hypertension requiring pharma-
cological treatment; age 75 years or older; diabetes 
mellitus; and prior stroke, transient ischaemic attack, 
or systemic embolus. 
Exclusion criteria included clinically significant 
mitral stenosis, conditions other than atrial fibrillation 
requiring anticoagulation, required aspirin treatment 
in a dose more than 165 mg/day or used in combination 
with a thienopyridine, recent ischaemic stroke, atrial 
fibrillation due to reversible causes, an increased bleed-
ing risk considered to be a contraindication for oral 
anticoagulation, and severe renal insufficiency (that is, 
serum creatinine >221.0 μmol/L or calculated creatinine 
clearance <0.42 mL/s).
Patients were randomised to either 5 mg apixaban 
twice daily (n=9120) or a dose adjusted regimen of 
 warfarin (n=9081). The target range for the interna-
tional normalised ratio was 2.0 to 3.0, using a blinded 
encrypted point of care device. If two or more of the fol-
lowing criteria were present at baseline, patients 
received an apixaban dose of 2.5 mg twice daily or 
matching placebo: age 80 years or older, body weight 
up to 60 kg, serum creatinine 132.6 μmol/L or more. The 
study was approved by appropriate ethical committees 
at all sites and all patients provided written informed 
consent.
Concomitant drug treatments and comorbidity
To investigate the association between the number of 
concomitant drugs and the extent of comorbidity, we 
assessed the number of drugs used for each patient. The 
study drug (apixaban or warfarin) and the matching 
placebo were counted as one drug. All treatments were 
categorised by drug class, according to the Anatomical 
Therapeutic Chemical classification system.24 
 Polypharmacy was defined as the use of five or more 
concomitant drugs.22
The use of drugs known to interact with apixaban or 
warfarin was assessed for each patient. For apixaban, 
we studied drugs known to inhibit both the cytochrome 
P450 (CYP) 3A4 enzyme as well as the P-glycoprotein as 
depicted by the US Food and Drug Administration.25  For 
warfarin, we studied the use of drugs known to inhibit 
or potentiate its anticoagulant effect with a high proba-
bility according to the American College of Chest Physi-
cians guideline.26
All analyses performed were based on the baseline 
medication burden. Only for the anticoagulant we stud-
ied premature permanent discontinuation of the study 
drug; for patients assigned to warfarin, we calculated 
the time in therapeutic range according to the 
Rosendaal method.27
Per protocol—the use of any concomitant drugs 
during the trial—was left to the discretion of the treat-
ing physician. The following concomitant drugs were 
prohibited in combination with the study drug: potent 
inhibitors of CYP3A4 (eg, azole antifungals, macrolide 
antibiotics, protease inhibitors, and nefazadone), aspi-
rin taken as a daily dose of more than 165 mg, other 
anticoagulant agents (eg, unfractionated heparin, low 
molecular weight heparin, direct thrombin inhibitors, 
pentasaccharides), and glycoprotein IIb/IIIa inhibi-
tors. If these agents were used during trial participa-
tion, the study drug was to be (temporarily) interrupted 
and restarted as soon as the prohibited drug was dis-
continued. During the trial, it was also advised to cau-
tiously use aspirin in combination with a 
thienopyridine, chronic daily use of a non-steroid 
anti-inflammatory agent, and cytotoxic or myelosup-
pressive therapy.
Clinical outcomes
We assessed outcomes in relation to the number of con-
comitant drug treatments used at the time of randomis-
ation, during a median follow-up of 1.8 years 
(interquartile range 1.3-2.3 years). The primary efficacy 
outcome was stroke (that is, abrupt onset of focal 
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 neurological symptoms lasting at least 24 h) or a 
 systemic embolism (that is, symptoms suggestive of an 
acute loss of blood flow to a non-cerebral artery, 
 supported by evidence of embolism from surgical 
 specimens, autopsy, angiography, or other objective 
testing). Key secondary efficacy outcomes included 
assessment of the type of stroke (ischaemic, haemor-
rhagic, or unspecified) and all cause death.
The primary safety endpoint was major bleeding 
according to the criteria set by the International 
Society on Thrombosis and Haemostasis, which 
includes any clinically overt bleeding event accom-
panied by one or more of the following: haemoglo-
bin drop of 20 g/L or more over a 24 h period, 
transfusion of two or more units of packed red blood 
cells, bleeding at a critical site (that is, intracranial, 
intraspinal, intraocular, intra-articular, pericardial, 
intramuscular with compartment syndrome, or ret-
roperitoneal), or fatal bleeding.28 Moreover, clini-
cally relevant non-major bleeding events were 
monitored, and were defined as all clinically overt 
bleeding not meeting the criteria of major bleeding 
but leading to hospital admission, physician guided 
medical or surgical treatment, or a change in anti-
thrombotic therapy. We defined the combined end-
point of net benefit as the combination of death, 
stroke, systemic embolism, and major bleeding.
statistical analysis
This post hoc analysis of ARISTOTLE was performed 
in 2015. Based on the tertiles of the distribution of the 
number of concomitant drugs used at baseline (that 
is, 0-5, 6-8, and ≥9 drugs), patients were classified in 
groups. Comorbidities, organised by organ system, 
were summarised for the three groups, as well as 
other baseline characteristics. A similar approach 
was followed for the different drug classes. Data were 
depicted as means and standard deviations for con-
tinuous variables and frequencies and percentages 
for categorical variables. We used one way analysis of 
variance and χ2 tests to compare groups. Efficacy, 
safety, and net benefit endpoints were compared 
among the three groups using rates per 100 patient 
years of follow-up and adjusted hazard ratios with 
95% confidence intervals. Adjusted hazard ratios 
were derived using Cox regression models adjusting 
for sex and age and country of randomisation. In 
these models, age was considered non-linear and 
included as a restricted cubic spline. We assessed the 
randomised treatment effect within each group 
(0-5, 6-8, ≥9 drugs) using a Cox regression model to 
estimate hazard ratios for apixaban versus warfarin 
along with 95% confidence intervals. The homogene-
ity of the randomised treatment effect across groups 
was tested by adding interaction terms to the Cox 
regression model.
The proportional hazard assumption was evaluated 
using scaled Schoenfeld residuals and no clinically rel-
evant departure from the assumption was observed. All 
the analyses were performed with SAS version 9.4 (SAS 
Institute).
Patient involvement
No patients were involved in designing the study, in 
assessing the burden of the intervention on patients, or 
in explicitly setting outcome measures; however, out-
comes were chosen to reflect daily practice described in 
earlier studies.29 Final study results of the ARISTOTLE 
trial were disseminated to study participants through 
their treating physicians.
Results
baseline characteristics and comorbidity
Table 1 depicts baseline characteristics of the study 
population, categorised by groups of the number of 
drug treatments. The randomised treatment was well 
balanced across groups, and no relevant differences 
between apixaban and warfarin was observed for any of 
the drug categories across the population (supplemen-
tary table 1).
Patients using more drug treatments were older, 
more often female, and less often warfarin naive at 
study entry (table 1). The CHADS2 and HAS-BLED scores 
increased with the increasing number of concomitant 
drug treatments. With the increasing number of drugs, 
the associated comorbidity increased significantly 
(table 1).
Concomitant drugs—classification according to 
organ or system
The median number of drug treatments used was six 
(interquartile range 5-9) and polypharmacy was pres-
ent in 13 932 (76.5%) patients (supplementary fig 1). 
Among the 18 201 ARISTOTLE participants, we saw 
marked regional differences in the number of drugs 
used: 53% (2385/4474) of patients enrolled in North 
America used nine or more drugs (United States 
1980/3417 (58%); Canada 405/1057 (38%)), compared 
with 10-21% for the other regions (table 1). Although 
there were more patients with comorbidity in four or 
more organ systems in the USA than in non-US coun-
tries (1389 (43.3%) v 2602 (20.5%)), we observed a 
greater number of drugs used in the USA regardless of 
the number of comorbidities.
Across groups of increasing number of drugs, the 
median number of represented drug classes increased 
from two (interquartile range two to three) to five (four 
to five), for patients using up to five drugs and for those 
using nine or more drugs, respectively.
Across the three study groups, there were no relevant 
differences between apixaban and warfarin regarding the 
proportion of patients in each of the defined drug classes. 
For each of the respective drug classes, the proportion of 
patients increased statistically significantly from the 
group using up to five concomitant drugs to the group 
using nine or more concomitant drugs. Across groups of 
increasing concomitant medication, the proportion of 
patients in the respective drug classes was higher in the 
USA than in non-US countries (supplementary table 2A 
and 2B). Despite this difference in prescription pattern, 
we saw a clear association between the number of con-
comitant drugs used at baseline and the number of 
comorbidities, both for the US and non-US populations.
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table 1 | baseline characteristics of aristOtle trial participants, by number of concomitant drugs used
Characteristic
no of drugs
P0-5 (n=6943) 6-8 (n=6502) ≥9 (n=4756)
Age (years, mean (SD)) 68 (10) 69 (10) 71 (9) <0.001
Male 4687 (67.5) 4107 (63.2) 2991 (62.9) <0.001
Weight (kg, mean (SD)) 81 (19) 84 (21) 89 (23) <0.001
Body mass index (mean (SD)) 28.2 (5.4) 29.5 (6.0) 30.7 (6.5) <0.001
Previous use of vitamin K antagonists >30 days 3555 (51.2) 3656 (56.2) 3190 (67.1) <0.001
Creatinine (mg/dL, mean (SD)) 1.02 (0.24) 1.06 (0.28) 1.12 (0.32) <0.001
Region of enrolment
 North America 736 (10.6) 1353 (20.8) 2385 (50.1)
<0.001
 Latin America 1809 (26.1) 1306 (20.1) 353 (7.4)
 Europe 3128 (45.1) 2811 (43.2) 1404 (29.5)
 Asia 1270 (18.3) 1032 (15.9) 614 (12.9)
HAS-BLED score (mean (SD)) 1.45 (0.96) 1.77 (1.02) 2.25 (1.05) <0.001
CHADS2 score (mean (SD)) 1.87 (1.02) 2.15 (1.08) 2.44 (1.17) <0.001
CHADS2 score
 ≤1 3093 (44.5) 2057 (31.6) 1033 (21.7)
<0.001 2 2309 (33.3) 2400 (36.9) 1807 (38.0)
 ≥3 1541 (22.2) 2045 (31.5) 1916 (40.3)
Randomised group
 Apixaban 3424 (49.3) 3320 (51.1) 2376 (50.0)
0.13
 Warfarin 3519 (50.7) 3182 (48.9) 2380 (50.0)
Low dose apixaban/placebo received (2.5 mg twice 
daily)
253 (3.6) 288 (4.4) 290 (6.1) <0.001
Cardiovascular comorbidities
 Coronary artery disease 1795 (25.9) 2184 (33.6) 2063 (43.4) <0.001
 Prior myocardial infarction 564 (8.1) 985 (15.2) 1036 (21.8) <0.001
  History of percutaneous coronary intervention or 
coronary artery bypass grafting
369 (5.3) 815 (12.5) 1292 (27.2) <0.001
 Congestive heart failure within 3 months 1931 (27.8) 2194 (33.7) 1416 (29.8) <0.001
 At least moderate valvular heart disease 926 (13.4) 1192 (18.3) 1116 (23.5) <0.001
 Syncope in past 5 years 258 (3.7) 279 (4.3) 322 (6.8) <0.001
 Hypertension with pharmacological treatment 5844 (84.2) 5762 (88.6) 4310 (90.6) <0.001
 Peripheral artery disease 193 (2.8) 290 (4.5) 401 (8.5) <0.001
 Aortic aneurysm 46 (0.7) 84 (1.3) 139 (3.0) <0.001
Neurological/cerebrovascular comorbidities
Carotid stenosis 54 (0.8) 93 (1.4) 190 (4.0) <0.001
Transient ischaemic attack 302 (4.4) 315 (4.8) 337 (7.1) <0.001
Stroke 808 (11.6) 750 (11.5) 569 (12.0) 0.77
Dementia 22 (0.4) 29 (0.5) 45 (1.0) <0.001
Epilepsy 22 (0.4) 49 (0.8) 41 (0.9) <0.001
Pulmonary comorbidities
 Chronic obstructive pulmonary disease 435 (6.3) 626 (9.7) 889 (18.7) <0.001
 Asthma 157 (2.3) 250 (3.9) 462 (9.7) <0.001
 Sleep Apnoea 145 (2.1) 262 (4.0) 606 (12.8) <0.001
Gastrointestinal comorbidities
 Dyspepsia 374 (5.4) 445 (6.9) 556 (11.7) <0.001
 Gastroesophageal reflux disease 315 (4.5) 527 (8.1) 1074 (22.6) <0.001
 Peptic ulcer disease 383 (5.5) 417 (6.4) 406 (8.5) <0.001
 Gastrointestinal surgery 509 (7.3) 606 (9.3) 575 (12.1) <0.001
 Chronic liver disease 190 (2.7) 193 (3.0) 121 (2.5) 0.39
Endocrine comorbidities
    Hypothyroidism or hyperthyroidism 429 (6.2) 733 (11.3) 878 (18.5) <0.001
    Diabetes mellitus 806 (11.6) 1603 (24.7) 2138 (45.0) <0.001
    End organ damage due to diabetes  
mellitus
75 (1.1) 219 (3.4) 459 (9.7) <0.001
Musculoskeletal comorbidities
    Falls within 1 year 140 (2.3) 215 (3.6) 398 (8.8) <0.001
    Previous non-traumatic fracture 299 (4.3) 339 (5.2) 436 (9.2) <0.001
    Osteoporosis 151 (2.2) 298 (4.6) 521 (11.0) <0.001
Renal comorbidities
    Chronic kidney disease 434 (6.3) 520 (8.0) 553 (11.6) <0.001
    Creatine clearance <50 mL/min 927 (13.4) 1112 (17.2) 970 (20.5) <0.001
(Continued )
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Clinical outcomes according to the number of 
concomitant drugs
Efficacy outcomes
With regard to the primary efficacy endpoint (stroke and 
systemic embolism), patients using more concomitant 
drugs were at higher risk, with an increase in event rates 
from 1.29 per 100 patient years for patients using up to 
five drugs to 1.57 per 100 patient years for patients using 
nine or more drugs (P<0.001; table 3). For the secondary 
efficacy outcomes, there was also a significant associa-
tion with the number of concomitant drugs. We saw a 
twofold increased risk for all cause death for patients 
using nine concomitant drugs or more compared with 
those using up to five concomitant drugs (P<0.001).
Safety outcomes
The risk of major bleeding for patients using six or more 
concomitant drugs was significantly higher than for 
those using up to five drugs (using 0-5 drugs as reference 
group; 6-8 drugs: adjusted hazard ratio 1.24 (95% confi-
dence interval 1.04 to 1.49); ≥9 drugs: 1.72 (1.41 to 2.10); 
table 3). When subdividing major bleeding according to 
the location, we observed no significant difference 
across groups for intracranial bleeding (P=0.73), while 
the event rate for gastrointestinal bleeding significantly 
increased with a higher number of concomitant drugs.
Net benefit outcome
With regard to the combined endpoint of stroke, sys-
temic embolism, major bleeding, and all cause death, 
event rates increased across groups (5.24, 6.59, and 8.92 
per 100 patient years for 0-5, 6-8, and ≥9 drugs, respec-
tively, P<0.001; table 3 ). This increase was associated 
with an adjusted hazard ratio of 1.84 (95% confidence 
interval 1.63 to 2.07) for patients using at least nine con-
comitant drugs compared with those using up to five 
concomitant drugs (table 3).
Other outcomes
With the use of increasing numbers of concomitant 
drugs, the risk of permanent discontinuation of study 
drug rose significantly (discontinuation rates 14.3, 15.0, 
and 17.4 per 100 patient years at risk for 0-5, 6-8, and ≥9 
drugs, respectively, P<0.001; table 3 ). Poor control of the 
international normalised ratio during follow-up (that is, 
time in therapeutic range <66%) was highest in the 
table 1 | baseline characteristics of aristOtle trial participants, by number of concomitant drugs used
Characteristic
no of drugs
P0-5 (n=6943) 6-8 (n=6502) ≥9 (n=4756)
Haematological comorbidities
    History of Anemia 210 (3.0) 359 (5.5) 676 (14.2) <0.001
    Thrombocytopenia (platelet at baseline <150×109/L) 510 (7.6) 467 (7.4) 332 (7.2) 0.77
    Bleeding history 779 (11.2) 1029 (15.8) 1232 (25.9) <0.001
No of organ systems affected (median (IQR)) 2, 1-3 2, 2-3 3, 2-4 <0.001
Data are no (%) of patients unless stated otherwise. Subcategorisation of all baseline characteristics per treatment allocation is presented in web table 1. 
CHADS2=congestive heart failure, hypertension, age (≥75 years), diabetes mellitus, and previous stroke/transient ischaemic attack/systemic embolism 
(doubled risk weight); HAS-BLED=uncontrolled hypertension, abnormal renal and liver function, prior stroke, bleeding history (or predisposition), labile 
international normalised ratio, age>65 years, drugs predisposing to bleed, and alcohol use disorders; IQR=interquartile range; SD=standard deviation.
table 2 | Distribution of drug classes used by aristOtle trial participants, by number of concomitant drugs used
Drug class
no of drugs
P0-5 (n=6943) 6-8 (n=6502) ≥9 (n=4756)
Alimentary tract and metabolism 962 (13.9) 3045 (46.8) 4094 (86.1) <0.001
Blood and blood forming organs (excluding apixaban/warfarin) 2282 (32.9) 4322 (66.5) 4116 (86.5) <0.001
Cardiovascular system 6460 (93.0) 6468 (99.5) 4737 (99.6) <0.001
Dermatological drugs 34 (0.5) 96 (1.5) 346 (7.3) <0.001
Genitourinary system and sex hormones 173 (2.5) 510 (7.8) 936 (19.7) <0.001
Systemic hormonal preparations, excluding sex hormones and insulins 181 (2.6) 508 (7.8) 852 (17.9) <0.001
Anti-infective drugs for systemic use 44 (0.6) 161 (2.5) 347 (7.3) <0.001
Antineoplastic and immunomodulating agents 14 (0.2) 60 (0.9) 152 (3.2) <0.001
Musculoskeletal system 202 (2.9) 688 (10.6) 1350 (28.4) <0.001
Nervous system 523 (7.5) 1448 (22.3) 2376 (50.0) <0.001
Antiparasitic products, insecticides, and repellents 0 (0.0) 13 (0.2) 46 (1.0) <0.001
Respiratory system 164 (2.4) 600 (9.2) 1336 (28.1) <0.001
Sensory organs 41 (0.6) 115 (1.8) 300 (6.3) <0.001
Various 126 (1.8) 247 (3.8) 630 (13.2) <0.001
Interacting drugs
 ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inhibitor 1128 (16.2) 1431 (22.0) 1301 (27.4) <0.001
 ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inducer 12 (0.2) 34 (0.5) 47 (1.0) <0.001
 ≥1 highly probable VKA inhibiting drug 8 (0.1) 19 (0.3) 33 (0.7) <0.001
 ≥1 highly probable VKA potentiating drug 973 (14.0) 1406 (21.6) 1387 (29.2) <0.001
 Use of acetylsalicylic acid, NSAIDs, or prednisone 956 (13.8) 2064 (31.7) 2362 (49.7) <0.001
Data are no (%) of patients. CYP=cytochrome P450; VKA=vitamin K antagonist, NSAIDs=non-steroidal anti-inflammatory drugs.
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patients using up to five concomitant drugs and 
decreased across the groups (53.2%, 50.2%, and 44.9% 
for 0-5, 6-8, and ≥9 drugs, respectively, P<0.001; table 3).
treatment effect
Figures 1 and 2 outline the treatment effect of apixaban 
versus warfarin for the different study outcomes, cate-
gorised by the number of concomitant drugs used at 
baseline.
For the primary efficacy outcome, risk reductions of 
apixaban versus warfarin were consistent, irrespective of 
the number of concomitant drugs used (Pinteraction=0.82), 
with lower event rates on apixaban for all groups. Also 
for the secondary efficacy outcomes, no significant 
interactions were observed.
With regard to major bleeding, relative risk reductions 
for apixaban versus warfarin fell with increasing num-
ber of concomitant drugs (Pinteraction=0.017), correspond-
ing to absolute rate reductions per 100 patient years of 
1.28, 0.82, and 0.66 for the three groups (0-5, 6-8, and ≥9 
drugs, respectively). For intracranial bleeding, the abso-
lute benefit on apixaban showed a numerical increase 
across the groups, by contrast with the numerical differ-
ences in major gastrointestinal bleeding observed 
between treatment groups. With regards to the com-
bined outcome of stroke, systemic embolism, major 
bleeding, and all cause death, we observed no signifi-
cant interaction between treatment groups (P=0.10). 
Rates of permanent study drug discontinuation were 
lower for apixaban in all groups (Pinteraction=0.36).
interacting drugs
The proportion of patients using an interacting drug 
increased across the groups of concomitant drug treat-
ments, both for CYP3A4 and P-glycoprotein inhibitors as 
warfarin potentiating drugs. At least one combined 
inhibitor of both the CYP3A4 enzyme and P-glycoprotein 
was used by 20.9% (1903/9120) of patients treated with 
apixaban, and 21.1% (1913/9081) of patients treated with 
warfarin used vitamin K antagonist potentiating drugs. 
For the concomitant use of aspirin, non-steroidal 
anti-inflammatory drugs, or prednisone, proportions 
were 13.8%, 31.7%, and 49.7% for the three groups (0-5, 
6-8, and ≥9 drugs, respectively; P<0.001).
Rates of major bleeding did not significantly differ 
between patients with or without combined CYP3A4 
and P-glycoprotein inhibitors (2.59 v 2.61 per 100 patient 
years, respectively). Moreover, no significant interac-
tion with the treatment allocation was observed 
(P=0.39; table 4). With regard to drugs known to poten-
tiate warfarin, we also observed no difference in the 
event rate of major bleeding for users versus non-users 
(2.60 v 2.61 per 100 patient years).
discussion
In this post hoc analysis of the ARISTOTLE trial, we 
observed that polypharmacy was present in three quar-
ters of patients and that the number of concomitant drug 
treatments is associated with increased comorbidity. 
Prescription patterns differed across regions, with 
about twice the number of concomitant drugs used in 
the USA versus non-US countries. Adverse clinical out-
comes occurred more frequently in patients treated 
with a higher number of concomitant drugs. The bene-
fits of apixaban in reducing stroke were preserved, 
regardless of the number of concomitant drugs taken. 
In terms of safety, although rates of major bleeding were 
consistently lower with apixaban than with warfarin, 
the magnitude of benefit with apixaban decreased with 
the increasing number of concomitant drug treatments.
Polypharmacy and adverse outcomes
Atrial fibrillation affects older patients, who have a vary-
ing extent of comorbidity and associated concomitant 
table 3 | efficacy and safety outcomes by number of concomitant drug treatments used by aristOtle trial participants
event
0-5 drugs 6-8 drugs ≥9 drugs
P
rate per 100 
patient years 
(no of patients)
adjusted 
hazard ratio 
(95% Ci)
rate per 100 
patient years 
(no of patients)
adjusted hazard 
ratio (95% Ci)
rate per 100 
patient years 
(no of patients)
adjusted hazard 
ratio (95% Ci)
efficacy outcomes
Stroke/SE 1.29 (166) Reference 1.48 (176) 1.270 (1.022 to 1.577) 1.57 (135) 1.539 (1.190 to 1.991) 0.004
Ischaemic or uncertain type of stroke 0.82 (106) Reference 1.11 (132) 1.475 (1.136 to 1.915) 1.15 (99) 1.738 (1.275 to 2.369) 0.001
All cause death 3.01 (396) Reference 3.80 (462) 1.409 (1.229 to 1.616) 4.70 (414) 2.031 (1.735 to 2.377) <0.001
safety outcomes
Major bleeding 1.91 (224) Reference 2.46 (267) 1.243 (1.036 to 1.491) 3.88 (298) 1.721 (1.414 to 2.095) <0.001
Intracranial 0.54 (64) Reference 0.55 (61) 1.025 (0.722 to 1.456) 0.62 (49) 1.153 (0.795 to 1.673) 0.73
Gastrointestinal 0.47 (56) Reference 0.71 (78) 1.498 (1.062 to 2.111) 1.15 (90) 2.429 (1.740 to 3.391) <0.001
Clinically relevant non-major bleeding 2.09 (243) Reference 2.47 (267) 1.183 (0.994 to 1.408) 3.30 (252) 1.574 (1.319 to 1.877) <0.001
Any bleeding 17.41 (1742) Reference 21.40 (1908) 1.167 (1.092 to 1.247) 29.63 (1766) 1.452 (1.348 to 1.565) <0.001
net benefit outcomes
Stroke/SE/major bleeding/all cause 
death
5.24 (665) Reference 6.59 (769) 1.320 (1.187 to 1.468) 8.92 (743) 1.838 (1.631 to 2.071) <0.001
Other outcomes
Permanent study drug 
discontinuation
14.32 (1699) Reference 14.99 (1655) 1.053 (0.982 to 1.129) 17.44 (1372) 1.218 (1.123 to 1.322) <0.001
Time in therapeutic range <66%* 53.2 (1823) Reference 50.2 (1564) 0.887 (0.805 to 0.977) 44.9 (1044) 0.716 (0.644 to 0.795) <0.001
Hazard ratios and P values adjusted by country (strata), sex, and age (spline). SE=systemic embolism.
*Values reported are percentage (number of patients) and unadjusted odd ratios for patients randomised to warfarin.
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drug treatments.30  Previous studies have reported rates 
of polypharmacy in 40-64% of patients with atrial fibril-
lation, with varying prescription patterns and inclusion 
and exclusion criteria.9 10
Various reports have demonstrated, for different clin-
ical conditions, that polypharmacy is associated with 
increased comorbidity.5-10 In addition, studies focusing 
on older populations have linked polypharmacy to 
adverse drug reactions, falls, disability, and frailty.6-8 In 
this context, patients with polypharmacy could consti-
tute a population with a differential response to oral 
anticoagulation.
Although differences in prescription thresholds 
could affect the classification of patients in individual 
cases, several reports have repeatedly demonstrated on 
a group level that polypharmacy is associated with 
comorbidity and adverse outcome, also in populations 
with atrial fibrillation.6-17 Our findings of higher risks of 
bleeding, stroke, and all cause mortality with increas-
ing numbers of drugs are in line with these previous 
observations.
Notably, this increased risk of adverse outcomes 
should be placed in the context of the association 
between the number of drug treatments and comorbid-
ities present at baseline, indicating a more frail status 
of patients with polypharmacy. If we were to adjust for 
these baseline differences, it is likely that the risk of 
adverse outcomes related to the number of drugs would 
diminish. However, we did not study the association 
between polypharmacy and adverse outcomes indepen-
dent of the baseline difference. On the contrary, we 
studied the number of concomitant drugs as a marker of 
comorbidity or frailty, and adverse outcome.
As such, we performed adjustments limited to age, 
sex, and country of randomisation. It was important to 
adjust for region, given the differences in prescription 
patterns between countries that are independent of dif-
ferences in comorbidity. It is striking that the USA had 
more use of polypharmacy than non-US countries, 
which was not solely explained by comorbidity.
Polypharmacy and treatment effect
Considering that patients with polypharmacy have a 
higher risk of adverse outcomes and multiple coexisting 
impairments, it is of special interest to study whether 
the main trial results of the ARISTOTLE study are con-
sistent among patients using many concomitant drug 
treatments. For the primary endpoint of stroke and sys-
temic embolism, we saw an absolute risk reduction 
from 1.60% per year with warfarin to 1.27% per year 
with apixaban (21% relative risk reduction in the com-
plete population, which was consistent irrespective of 
the number of concomitant drugs used).19
Overall, the use of apixaban was associated with an 
absolute risk reduction in major bleeding from 3.09% to 
2.13% per year when compared with warfarin (relative 
risk reduction 31%).19 However, we observed a signifi-
cant treatment interaction with relative risk reductions 
of apixaban varying from 50% (0-5 drugs) to 28% (6-8 
drugs) and 16% (≥9 drugs), respectively. Importantly, 
the risk reduction of intracranial bleeding did not 
diminish with an increasing number of concomitant 
drugs. Therefore, the fact that the relative benefit of 
apixaban over warfarin appears to diminish across 
groups is due to other types of major bleeding. For 
example, with increasing numbers of drug treatments, 
the numerical difference in gastrointestinal bleeding 
events shifts from a benefit for apixaban (0-5 drugs) to 
no apparent difference (≥9 drugs) between both oral 
anticoagulants.
The ROCKET AF trial, with overall similar rates of 
major bleeding for rivaroxaban and warfarin, also 
showed a treatment interaction for major bleeding.10 
The hazard ratio for major bleeding in patients using 
fewer concomitant drugs (0-4) was lower than that 
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Fig 1 | association between randomised treatment and main 
outcomes, by number of concomitant drugs used at 
baseline by aristOtle trial participants
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observed in the entire study population (adjusted haz-
ard ratio 0.69 (95% confidence interval 0.51 to 0.94) v 
1.04 (0.90 to 1.20)). For mortality, there was no differ-
ence in treatment effect of rivaroxaban in patients with 
polypharmacy. In the ARISTOTLE trial, apixaban 
reduced the risk of mortality from 3.94% to 3.52% per 
year when compared with warfarin in the main study—a 
relative risk reduction of 11% that was consistent 
regardless of the number of concomitant drug treat-
ments.19
In the ARISTOTLE trial as well as in the ROCKET AF 
trial, patients with polypharmacy were older.10  None-
theless, the relative reduction of both apixaban and 
rivaroxaban on major bleeding proved to be consistent 
across the different age groups in previously reported 
post hoc analyses.20 31 Importantly, this implies that our 
findings cannot be inferred to older patients in general. 
In fact, our findings are irrespective of age and sex, and 
refer to the group of patients, both younger and older, 
with multiple comorbidities and drug treatments.
Possible explanations for the attenuation of the 
observed safety benefit of apixaban with increasing 
concomitant drugs include effects of comorbidity and 
drug-drug interactions, or the play of chance. We 
demonstrated that various coexisting diseases (chronic 
obstructive pulmonary disease, gastrointestinal dis-
ease, renal impairment) were more frequent with 
increasing numbers of concomitant drugs. Of interest, 
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Fig 2 | treatment comparisons for efficacy, safety, and net benefit outcomes between apixaban and warfarin according to 
the number of concomitant drugs used by aristOtle trial participants at baseline
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given the consistent risk reduction of apixaban for 
intracranial bleeding, the treatment interaction for 
major bleeding is related to other major bleeding. Risk 
factors for gastrointestinal bleeding complications (eg, 
previous gastric ulcers; gastrointestinal surgery; dys-
pepsia; use of aspirin, prednisone, or non-steroidal 
anti-inflammatory drugs) were more prevalent among 
patients with polypharmacy. Other non-gastrointesti-
nal risk factors for bleeding were also more often com-
mon in patients using more concomitant drugs (eg, 
older age, renal impairment, anaemia, diabetes, and 
previous bleeding).32
Other aspects that could account for the reduced ben-
efit of apixaban in patients using nine concomitant 
drugs or more are the higher rates of permanent study 
drug discontinuation and lower proportion of patients 
who were vitamin K antagonist naive (supplementary 
table 1).33  The lower rates of patients on study medica-
tion may have blunted the observed risk reduction of 
apixaban in this group. In addition, bleeding rates on 
warfarin are usually lower in patients with prior experi-
ence vitamin K antagonists. Finally, the better control of 
international normalised ratio in the patients with more 
than nine concomitant drug treatments may have 
diminished bleeding rates on warfarin.34 35
For drug-drug interactions, we specifically studied 
the effect of warfarin potentiating drugs and the combi-
nation of CYP3A4 and P-glycoprotein inhibitors, given 
the possibility of higher plasma concentrations of apix-
aban with these agents. However, we saw no evidence 
of differential treatment effect between apixaban and 
warfarin across groups of the number of concomitant 
drugs when accounting for warfarin or apixaban poten-
tiating drugs.
The effects of non-vitamin K antagonist oral anticoag-
ulants in patients with polypharmacy have also been 
studied in a pooled analysis of data, in the setting of 
secondary prevention after a venous thromboembo-
lism.15 For major bleeding, there was no treatment inter-
action when comparing the safety of dabigatran versus 
warfarin in patients using three or fewer concomitant 
drugs with those using more than three concomitant 
drugs. However, these patients were much younger and 
less fragile than patients with atrial fibrillation.
With regards to symptomatic venous thromboembo-
lism, the issue of a potential different response to oral anti-
coagulation therapy in patients considered to be fragile 
has been studied in more detail.36  In this study, patients 
were considered to be fragile if they were over 75 years 
old, had a low body weight (<50 kg), or had impaired renal 
function (creatinine clearance <0.83 mL/s). Although 
this certainly identifies patients at risk, incorporation of 
multiple comorbidities would allow for a more refined 
identification of frail patients within these specific 
 subgroups.37
In summary, polypharmacy could be a marker of 
multimorbidity and a predictor of adverse outcomes, 
and it might provide a first general impression of a 
patient’s frailty. Future research on a differential 
response with oral anticoagulation therapy in patients 
with multimorbidity should focus on incorporation of 
the key frailty criteria. For example, the Fried criteria 
can help to identify higher risk patients who are often 
under-represented in clinical trials.38  This group may 
deserve additional attention, as far as the generalisabil-
ity of trial data is concerned, not only in the field of anti-
coagulation therapy but also for other treatments.39
study limitations 
This study had several limitations. Firstly, it was a post 
hoc analysis, although there was a prospective, detailed 
analysis plan. Secondly, the analyses were based on the 
drug burden at baseline, without information on drug 
changes, reason, or appropriateness of drug prescrip-
tion. However, with polypharmacy that is often driven 
by chronic medical conditions, substantial reductions 
in the number of drugs are not likely. Thirdly, as the 
number of drugs might not only be driven by the extent 
of comorbidity, but also by prescription patterns, we 
acknowledge that this might have affected classifica-
tion on an individual level. However, on a group level, 
the use of polypharmacy has repeatedly demonstrated 
to be a marker of the extent of comorbidity and associ-
ated with adverse outcome. 
The cut-off value of five or more drugs is arbitrary, 
although it has been used in many previous reports. 
Given that three quarters of patients would qualify for 
polypharmacy according to this definition, our statisti-
cal approach was not arbitrary, but based on a common 
approach of dividing our data into groups to explore 
polypharmacy across categories that are sufficiently 
large to avoid the hazard of small subgroups. With 
regard to generalisability, our findings might not apply 
to an unselected population with atrial fibrillation, 
given the selection that occurs when enrolling patients 
in clinical trials.
Conclusions
In this population with atrial fibrillation on oral anti-
coagulation therapy, polypharmacy (≥5 drugs) was 
observed in three quarters of patients. The extent of 
comorbidity increased with greater numbers of 
table 4 | Major bleeding rates with apixaban or warfarin according to use of interacting drugs by aristOtle trial 
participants
interacting drugs
use of potentiating drug (rate per 
100 patient years (no of patients))
no use of potentiating drug (rate per 
100 patient years (no of patients))
Pinteractionapixaban Warfarin apixaban Warfarin
≥ 1 combined P-glycoprotein and weak/
moderate/strong CYP3A4 inhibitor
2.27 (72) 2.91 (93) 2.10 (255) 3.14 (369) 0.39
≥1 highly probable VKA potentiating drug 2.03 (62) 3.16 (96) 2.16 (265) 3.07 (366) 0.64
CYP=cytochrome P450; VKA=vitamin K antagonist.
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 concomitant drugs, which was irrespective of regional 
prescription patterns. Mortality, stroke, and major 
bleeding were also more frequent with increasing 
numbers of drugs. As for a potential differential 
response to anticoagulation therapy in this context, 
we observed that apixaban was superior to warfarin in 
terms of efficacy, regardless of the number of drugs 
taken, whereas its magnitude of benefit on major 
bleeding decreased with higher numbers of concomi-
tant drugs. Important differences in the comorbidity 
profile could account for this, and it did not appear 
that warfarin or apixaban potentiating drugs (CYP3A4, 
P-glycoprotein inhibitors) explained this observed
treatment interaction. In summary, apixaban is more
effective than and is at least as safe as warfarin in
patients with atrial fibrillation, regardless of poly-
pharmacy.
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